In many hematopoietic malignancies, c-Myb, a nuclear transcription factor of hematopoietic cells, is an activated oncogene. To achieve a specific inhibition of hematopoietic tumor growth, an inducible fusion protein consisting of the Myb DNA binding domain (DBD) and the active repressor domain KRAB, the Krü ppel-associated box of the developmental zinc-finger protein KOX-1, was generated. The MybDBD-KRAB fusion protein is a potent repressor of Myb-induced gene expression from Myb-responsive reporter genes containing several Myb binding sites. MybDBD-KRAB expressed in the human hematopoietic promyelocytic cell line HL60 significantly reduces cell proliferation by inducing apoptosis. Expression of MybDBD-KRAB in subcutaneously injected HL60 cells leads to inhibition of tumor formation in nude mice. The MybDBD-KRAB effect is specific to cell lines expressing c-Myb. It is conceivable to fuse the KRAB domain to other DBDs of oncogenic transcription factors and target them to their respective DNA response elements to selectively drive tumor cells into apoptosis. Cancer Gene Therapy (2000) 7, 963-972
T ranscriptional activators are capable of activating transcription from their cognate DNA response elements located in the promoter/enhancer region of cellular genes. Transcription factors consist of modules specific for distinct functions, such as DNA binding, transactivation, dimerization, or coactivator binding. Many constitutively activated transcription factors play key roles as oncogenic proteins in malignant transformation, including Myc, Fos, Jun, and Myb. C-Myb is essential for proliferation of immature hematopoietic cells and is highly expressed during the early stages of hematopoietic differentiation and in various hematopoietic malignancies. 1, 2 The structure of c-Myb consists of three domains, an amino terminal DNA binding domain (DBD) comprising three repeats of 21 amino acids, a highly acidic transactivating domain, and two negatively regulating domains, which are absent in the viral v-Myb. 3 V-and c-Myb bind to their specific DNA binding sequence and transactivate cellular target genes such as the promyelocytic-specific mim-1 gene. 4 Regulation of transcription involves activation as well as repression. 5, 6 Repressors, also designated as silencers, 5 possess intrinsic repressing activity. These, for instance, are able to inhibit the initiation of transcription by directly interacting with the general transcription machinery. 5, 6 In addition, they also mediate long-range effects through chromatin condensation, leading to inactivation of gene expression. 5, 6 Recently, the repressor KOX-1 has been described, which is similar to the Drosophila developmental transcription factor Krüp-pel. 7, 8 KOX-1 contains in the C terminus 11 tandemly repeated zinc fingers, which mediate DNA binding and a Krüppel-associated box (KRAB) at the N terminus. 7 The KRAB domain no longer binds to DNA but can function as a transcriptional repressor when targeted to DNA through fusion to a heterologous DBD. 8 KRAB was chosen for this study because it is known to be one of the strongest transcriptional repressors in mammalian organisms. We produced fusion proteins with the KRAB domain and the MybDBD and studied their effects in vivo. MybDBD-KRAB-transfected human hematopoietic promyelocytic HL60 cells were strongly repressed in proliferation and, when injected into nude mice, were incapable of forming persisting tumors. We show that this observation is due to the induction of apoptosis. Fusion of the KRAB domain to the DBD of other tissue-specific oncogenic transcription factors and targeting to specific DNA response elements could be envisaged as a strategy to drive cells of interest into apoptosis.
MATERIALS AND METHODS

Cell culture and transfection
HL60 and SK-Mel 15 cells (kindly provided by T. J. Gonda, Hanson Centre for Cancer Research, Adelaide, Australia) were maintained at 37°C, 5% CO 2 in RPMI 1640 medium containing 10% fetal bovine sera, 100 U/mL penicillin G, 100 mg/mL streptomycin sulfate, and 2 mM L-glutamine (Life Technologies, Gaithersburg, Md). 293T and MC57 cells were cultured in Dulbecco's modified Eagle's medium supple-mented as described above. Transfections of the plasmids were performed using either Lipofectamine (Life Technologies, Basel, Switzerland) or Superfect (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. To generate stable transfectants of HL60 cells, clones growing in soft agar containing 0.5 mg/mL G418 (Mediatech, Herndon, Va) were isolated and further selected with G418 (0.5 mg/mL) in liquid culture. SK-Mel 15 and MC57 cells were transfected and were directly selected 48 hours later in G418 (1 mg/mL) containing medium.
Cloning strategies
Three constructs were used, coding for MybDBD, MybDBD-KRAB, and KRAB. MybDBD represents the EcoRI-HindIII fragment of the human c-myb gene (nucleotides 1 through 639), which was excised from the previously described human c-myb expressing plasmid pHM1. 9 KRAB corresponds to KRABS A and B of the KOX-1 gene (nucleotides 1 through 228) described previously. 10 MybDBD, KRAB, and MybDBD-KRAB fusion protein coding fragments were inserted into the pCATCH-NLS plasmid. 11 The v-Myb expressing construct was expressed from pVM1. 12 MybDBD, KRAB, and MybDBD-KRAB were also expressed from pSP64-Mxp constructs, 13 rendering them interferon-␣ (IFN-␣) inducible. pSV2-neo 14 harboring the neomycin resistance gene was used to produce stable cell lines.
Immunofluorescence analysis
HL60 cells and stable MybDBD-KRAB, MybDBD, or KRAB transfectants thereof were treated with 1000 international units (IU)/mL human IFN-␣ (Roferon A; Roche, Basel, Switzerland) for 24 hours. Subsequently, the cells were harvested, fixated, and immunostained as described previously by Dreiding et al 15 using the M2 anti-FLAG monoclonal antibody (mAb) (Kodak, New Haven, Conn).
Immunoprecipitation and Western blot analysis
Immunoprecipitation was carried out using a polyclonal sheep anti-Myb antibody as described previously. 16 Whole cell lysates were prepared from 1 ϫ 10 6 viable HL60 cells and 2 ϫ 10 7 SK-Mel 15 and MC57 cells (counted by trypan blue exclusion). For specific competition, a recombinant carboxyl-terminally deleted Myb protein was added to the anti-Myb antibodycoupled Sepharose beads. For Western blotting, nuclear extracts of transiently transfected 293T cells or stably transfected HL60, SK-Mel 15, and MC57 cells were prepared as described elsewhere, 17 and Western blot analysis was carried out using the M2 anti-FLAG mAb.
In vitro assay for quantification of ␤-galactosidase activity
The viral and eukaryotic promoters were cloned upstream of the lacZ, gene of the CMVlacZ plasmid (a gift from Dr. S. Rusconi, University of Fribourg, Fribourg, Switzerland) by replacing the cytomegalovirus promoter. 293T cells were cotransfected with 50 ng of the resulting constructs and 100 ng of MybDBD-KRAB. After 48 hours, quantitative liquid o-nitrophenyl-␤-D-galactopyranoside assays were performed essentially as described previously. 18 Chloramphenicol acetyltransferase (CAT) ELISA 293T cells were cotransfected by Lipofectamine with 50 ng of p(mim-1) 6 CAT reporter, based on the pCAT-E plasmid (Promega, Madison, Wis), with 18 ng of pVM1 12 (v-Myb) effector plasmid, and with various amounts of pCATCH-KRAB, pCATCH-MybDBD, and pCATCH-MybDBD-KRAB, respectively. The total amount of transfected DNA per reaction was adjusted to 150 ng with the empty parental pCATCH-NLS expression vector. Cells were harvested at 48 hours posttransfection, the protein concentration was determined by the Bradford dye binding assay, 19 and the subsequent CAT ELISA (Roche) was performed according to the manufacturer's protocol.
Growth curves
Parental and stably transfected cells were maintained at 37°C, 5% CO 2 , and at a cell density that allowed continuous growth over time; suspension cells were always kept at a density of Ͻ5 ϫ 10 6 cells/mL, and adherent cells were always diluted 1/5 before they reached confluency. For transgene expression, IFN-␣ was added at a concentration of 1000 IU/mL every 2-3 days. The number of viable cells was counted in a Neubauer chamber in quadruplicate using trypan blue dye.
Confocal microscopy of 4Ј,6-diamidino-2-phenylindole (DAPI)-stained cells HL60 cells and stable transfectants thereof were cultured in the presence or absence of 1000 IU/mL IFN-␣ and were diluted 1/2 or 1/4 every other day according to their average doubling-time. After 7 days, the cells were stained with DAPI. Briefly, cells were rinsed with phosphate-buffered saline (PBS) and ϳ5 ϫ 10 4 cells in 100 L of PBS were transferred to poly-L-lysine pretreated coverslips and incubated at 37°C for 45 minutes. Subsequently, the cells were fixed in 3% fresh paraformaldehyde, stained with DAPI in methanol (0.5 mg/mL) at 37°C for 15 minutes, and embedded in Mowiol (Hoechst, Frankfurt, Germany).
Detection of apoptotic cells with annexin Vfluorescein isothiocyanate (FITC)/propidium iodide (PI)
During IFN-␣ treatment over a time period of 5 weeks, aliquots of 1 ϫ 10 6 cells were harvested at the indicated timepoints, washed once in PBS, and stained with annexin V-FITC (Ann V) and PI according to the manufacturer's recommendations (Boehringer-Mannheim, Mannheim, Germany). Early apoptosis was detected by flow cytometry analysis (FACScalibur; Becton Dickinson, East Rutherford, NJ) exhibiting an Ann V ϩ /PI Ϫ staining pattern. Cells treated for 48 hours with the unspecific protein kinase C (PKC) inhibitor staurosporine (STS) at a concentration of 1 M served as a positive control for apoptosis.
Cell cycle analysis
Parental HL60 cells or stable transfectants thereof were continuously treated with IFN-␣ and harvested, washed twice with PBS, and fixed overnight in 70% ethanol at 4°C. Subsequently, these cells were treated with 1 mg/mL deoxyribonuclease-free ribonuclease and 0.4 mg/mL PI in 1 mL of PBS for 30 minutes at 37°C. Subsequently, the cells were analyzed by flow cytometry using a FACScalibur (Becton Dickinson). Fluorescence measurements were accumulated to form a distribution curve of DNA content.
Soft agar colony assay
A total of 1 ϫ 10 4 parental or transfected HL60 cells were plated in 0.3% top agarose over 0.5% bottom agarose in the absence or presence of 1000 IU/mL IFN-␣ as described elsewhere. 20 The cells were fed by changing the medium supplemented with IFN-␣ twice a week. Foci (Ͼ20 cells) were counted after 2 weeks.
Tumorigenicity in nude mice
Suspensions of 1 ϫ 10 7 cells per 300 L were injected subcutaneously into cyclophosphamide-treated adult ICR nude mice. Cyclophosphamide (35 mg/kg body weight) was administered intraperitoneally (i.p.) 72 hours and 24 hours before HL60 tumor cell challenge to allow formation of solid granulocytic sarcomas. 21 At 24 hours after cell injection, mice were treated with 200,000 IU of human IFN-␣ by the i.p. route. The IFN-␣ treatment was repeated every 72 hours for a total of 30 days. Tumor volumes were determined by measuring the largest diameter (d1) and the perpendicular diameter (d2) and calculated according to the following formula: d1 ϫ d2 2 ϫ 0.5.
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RESULTS
Gene repression through MybDBD-KRAB
The effect of MybDBD-KRAB on the transcriptional activity of v-Myb was first analyzed using various promoters, some of which are known to be regulated by vor c-Myb. Myb-responsive elements are found in the mim-1 promoter, 4 in the Rous sarcoma virus-long terminal repeat (LTR), 23 and in the simian virus 40 enhancer/promoter element. 24 Expression of a lacZ reporter gene from these promoters was repressed by MybDBD-KRAB, whereas expression from the LTR of Moloney murine leukemia virus, from HTLV-1, the immediate early promoter of cytomegalovirus, or from the IFNresponsive promoter Mx1 was unaffected (Fig 1A) .
Additional studies were performed using the CAT reporter gene under the control of the mim-1 promoter, containing a 6-fold repeat of Myb binding sites ((mim-1) 6 ).
12 V-Myb was cotransfected with the (mim-1) 6 CAT reporter gene and with MybDBD-KRAB-, MybDBD-, and KRAB-expressing constructs. Expression of Myb-DBD-KRAB, MybDBD, and KRAB was verified by immunofluorescence analysis with transiently transfected 293T cells (data not shown). CAT expression was measured by ELISA and equalized to the protein expression levels (Fig 1B) . MybDBD-KRAB repressed CAT expression in a concentration-dependent manner up to 15-fold more than MybDBD (Fig 1B, (Fig 2B) . HL60 cells, which were transfected with constructs directing the expression of KRAB, MybDBD, or MybDBD-KRAB from the Mx1 promoter, accumulate these proteins only after IFN-␣ treatment. Detection of KRAB, MybDBD, or MybDBD-KRAB in stably transfected HL60 cells was carried out either by immunofluorescence analysis after IFN-␣ treatment (Fig 2A) or Western blot analysis (Fig 2C) . Due to its small size of 9 kDa, KRAB could not be detected by the Western blot method.
First, the influence of MybDBD, MybDBD-KRAB, and KRAB on the growth properties of transfected HL60 cells was examined (Fig 2, D and E) . Upon IFN-␣ induction, HL60 cells expressing MybDBD-KRAB continued to grow for 2 weeks and then started to die off. In contrast, MybDBD-transfected HL60 cells, although showing a reduction of proliferation, did not die even after 40 days of IFN-␣ treatment (Fig 2, compare D and  E) . The observed reduction in cell proliferation of IFN-␣-induced versus uninduced HL60 cell lines (Fig 2,  compare D and E) is due to the presence of IFN-␣. 27 None of the stably transfected non-hematopoietic cell lines constitutively expressing MybDBD, MybDBD-KRAB, and KRAB showed an altered proliferation when compared with the respective parental cell line (Fig 2, F and G) .
MybDBD-KRAB induces apoptosis in HL60 cells
To characterize the effect of MybDBD-KRAB on HL60 cell proliferation, morphological changes were analyzed. Recently, Friedman et al 28 suggested that KRAB-mediated repression would lead to cell death by chromatin condensation and a general inhibition of transcription. Based on this hypothesis, MybDBD-KRAB-mediated repression targeted to Myb binding sites might specifically result in growth inhibition of Myb-dependent hematopoietic HL60 cells. Furthermore, MybDBD with or without a KRAB fusion partner might function as a competitive inhibitor of Myb. 29 Chromatin condensation and changes characteristic for apoptotic cell death can be determined by DAPI staining. 30 To this end, KRAB-, MybDBD-, and Myb-DBD-KRAB-expressing HL60 cells were harvested after 7 days of IFN-␣ treatment, stained with DAPI, and analyzed by phase contrast (Fig 3A, top) and scanning confocal microscopy (Fig 3A, bottom) . The latter method revealed chromatin condensation in ϳ75% of the cells transfected with MybDBD-KRAB (Fig 3A,  bottom right panel) . In contrast, when MybDBD or KRAB was expressed, only 20% or 5% of the cells, respectively, showed chromatin condensation (Fig 3A,  bottom middle and left panel) .
In an additional analysis, stably transfected HL60 cell lines were analyzed by double-staining with FITC-labeled annexin V 31 and PI, allowing discrimination of apoptotic from necrotic cells via fluorescence-activated cell sorter analysis (Fig 3B) . As a positive control for apoptosis, the unspecific PKC inhibitor STS, a known apoptosis inducer, 32 was used (Fig 3B) . When Myb-DBD-KRAB-expressing cells were treated for 37 days with IFN-␣ and subsequently tested for annexin and PI double-staining, 43.2% proved to be apoptotic and 23.4% proved to be necrotic (Fig 3B, fourth panel in the  bottom) . In contrast, only a small fraction of MybDBDor KRAB-expressing cells were apoptotic or necrotic (Fig 3B, fourth panels in the middle and top) . Before the observed decrease in cell proliferation of MybDBD-KRAB-expressing HL60 cells (10 days of IFN-␣ induction; see Fig 2D) , most of these cells were viable, with only 5.7% being apoptotic and 4.1% being necrotic ( Fig  3B, third panel in the bottom) . For KRAB-and Myb-DBD-expressing HL60 cells, these ratios were similar (Fig 3B, third panels in the top and middle) . Apoptosis was also confirmed by genomic DNA laddering (data not shown).
Finally, MybDBD-KRAB-transfected HL60 cells treated with and without IFN-␣ were stained with PI and analyzed with a fluorescence-activated cell sorter ( Fig  3C) . Fragmented DNA manifests itself in a hypodiploid pre-G 1 peak, which is a sign of apoptosis. 33 A total of 35% of MybDBD-KRAB-transfected HL60 cells treated with IFN-␣ for 31 days were apoptotic (Fig 3C, lower  right panel) , whereas only 3-13% of apoptotic cells were observed in all control experiments performed.
Effects of MybDBD-KRAB on tumorigenicity of HL60 cells
To measure the influence of MybDBD-KRAB on the transformation capacity of HL60 cells in culture, focus formation was assessed by a soft agar colony assay. Colonies were allowed to grow for 2 weeks in the absence or presence of IFN-␣. Expression of MybDBD-KRAB led to a strong reduction in the number of colonies, whereas expression of MybDBD alone had an intermediate effect (Fig 4A, compare Finally, we investigated the influence of MybDBD-KRAB on the tumor formation of HL60 cells after subcutaneous injection into nude mice. Starting 1 day after the injection of 1 ϫ 10 7 stable MybDBD-KRABtransfected HL60 cells, 200,000 U of IFN-␣ were administered i.p. every 3 days for 4 weeks. Tumor volumes are represented in Figure 4B . MybDBD-KRAB-expressing HL60 cells were only capable of transiently forming small tumors, and these tumors completely disappeared 25 days after tumor cell inoculation. Even after cessation of the IFN-␣ treatment, these nude mice remained tumor free for Ͼ90 days (Fig 4B) . MybDBD-expressing HL60 cells showed only a moderately reduced capability to form tumors, and in no case led to an eradication of the tumor (Fig 4B) . Next, after 10 days of IFN-␣ treatment, histological analyses of tumors derived from MybDBD-KRAB-transfected and parental HL60 cells were performed. The sections showed the typical features of highly proliferating leukemic malignancies, including a relatively uniform population of numerous cells in mitosis (Fig 4, C and E) . During the phase of tumor remission (day 20 of IFN-␣ treatment), cellular pleomorphism and irregular clumps of cells, distributed in a diffuse area of necrosis, could be observed (Fig 4D) . Mitotic activity was greatly diminished, and no local infiltration of inflammatory monocytic cells (mainly natural killer cells and macrophages in nude mice) was observed when compared with the control sections ( Fig  4F) . 
DISCUSSION
The genetic background for the excessive proliferation of human myeloid leukemia cells is the overexpression of the proto-oncogene c-Myb. 1 Furthermore, c-Myb has been suggested to be a survival factor responsible for the maintenance of human cancers. 29 In this study, we analyzed two different negative interfering Myb mutants, MybDBD and MybDBD-KRAB. MybDBD is a competitive inhibitor of c-Myb, whereas MybDBD-KRAB is an active repressor of c-Myb-dependent gene expression. Comparison of the two mutants allowed us to determine the contribution of the KRAB domain on the proliferation and differentiation of the human promyelocytic cell line HL60 in culture and in the living organism.
MybDBD alone can function as a competitive inhibitor of endogenous c-Myb in cultured cells, leading to reduced c-Myb-dependent reporter gene expression in transient transfection experiments (Fig 1, A  and B) , 34 to an inhibition of proliferation (Fig 2E) , and to reduced colony formation (Fig 4A) . However, competition for DNA binding sites by MybDBD was not sufficient to prevent tumor formation in a nude mouse model (Fig 4B) , although reduced tumor volumes were observed. In contrast, MybDBD-KRAB is able to completely suppress tumor formation in nude mice. These findings clearly indicate that the repressor function of KRAB fused to the MybDBD is responsible for overcoming the oncogenic activity of overexpressed c-Myb (Fig 4) .
MybDBD-KRAB is thought to block transcription in an orientation-and distance-independent manner by actively inhibiting the formation of an active transcription complex on the DNA. KRAB, in combination with its corepressor KRAB-associated protein 28 (also known as transcription inhibitory factor-1␤), 35 may force the packaging of promoters into nucleosomes, thereby preventing transcription factors from binding. 36 The inhibitory effect of MybDBD-KRAB on HL60 cell proliferation in cell culture and in the living organism occurs after a relatively long lag-phase of Ͼ2 weeks. This finding supports the idea that KRAB, once targeted to DNA by the fused DBD, may exert its inhibitory function by inducing chromatin condensation. Chromatin reorganization is known to involve slow processes, such as DNA methylation at CpG sites. 35 Furthermore, Bodnar and Bradley 37 described the switch from chromatin extension to condensation with an increased fraction of DNA bound to the nuclear matrix as a timeconsuming step.
The fact that not all Myb-DBD-KRAB-transfected cells were killed by IFN treatment after 37 days might be explained by the possibility that a small proportion of cells reduced or even lost the expression of Myb-DBD-KRAB during IFN treatment. Alternatively, a small proportion of cells might have become resistant to the action of Myb-DBD-KRAB by mutations in genes required for the Myb-DBD-KRAB-mediated chromatin condensation and apoptosis. A possible explanation for the observation that MybDBD-KRAB-transfected tumor cells were eradicated in nude mice is that this eradication could be due to an increased activity of natural killer cells in response to extensive apoptosis. Alternatively, it could be the result of a poor "plating efficiency" of HL60 cells in vivo.
Formally it is possible that the observed growth inhibitory effect seen with Myb-DBD-KRAB-transfected HL60 cells could be due to an increased sensitivity to IFN as a consequence of Myb-DBD-KRAB expression. However, this possibility is highly unlikely, because initial experiments with transfected HL60 cells expressing Myb-DBD-KRAB under the control of a constitutive promoter also resulted in strongly reduced proliferation.
C-Myb also has a role in hematopoietic cell differentiation. 1 The absence of differentiation markers on Myb-DBD-KRAB-expressing HL60 cells excludes differentiation as the reason for the observed block in cell proliferation. These MybDBD-KRAB-expressing HL60 cells showed no signs of differentiation because neither macrophage-nor granulocyte-specific cell surface markers were expressed (data not shown). These findings are in line with the observations of Anfossi et al, 38 who showed that c-myb antisense oligonucleotides inhibit cell proliferation but do not induce maturation of HL60 cells.
It has been demonstrated previously that Bcl-2 expression is induced by c-Myb and that down-regulation of c-Myb leads to reduced expression of Bcl-2 and hence to apoptosis. 29, 39 In that study, MybDBD was fused to the repressor domain of the Drosophila protein Engrailed (En) and expression of MybDBD-En in the thymoma cell line EL4 was shown to strongly reduce Bcl-2 levels within 4 days, leading to apoptotic cell death. 29 In our study, a slight reduction of Bcl-2 expression of 15% was observed after 31 days of IFN-␣-induced expression of MybDBD-KRAB in HL60 cells. A possible explanation is that MybDBD-KRAB is expressed at a much lower level than endogenous c-Myb in transfected HL60 cells (Fig 2, compare B with C) and therefore is not able to efficiently compete for Myb-responsive DNA sequences. The small reduction in Bcl-2 expression is unlikely to account for the observed apoptosis, suggesting that the apoptotic cell death of the transfected HL60 cells is mediated by a Bcl-2-independent mechanism. Indeed, for HL60 cells, a Bcl-2-independent induction of apoptosis by PKC inhibitors such as STS has been described. 40 MybDBD-KRAB-induced apoptosis is specific for hematopoietic Myb-overexpressing tumors, as produced by HL60 cells, because no effect of MybDBD-KRAB on the proliferation of human SK-Mel 15 melanoma cells or mouse MC57 fibrosarcoma cells was detected. These control cell lines express very low or no detectable levels of c-Myb, respectively, and therefore the Myb-responsive DNA sequences may be occluded by nucleosomes (Fig 2B) .
In summary, we provide direct evidence that the KRAB domain fused to the DBD of an overexpressed oncogene in its corresponding malignancy, human promyelocytic leukemia, is sufficient to produce a tumor suppressor effect in vivo that is irreversible even when the suppressor is no longer induced. Furthermore, our results demonstrate the limited effect of MybDBD alone as a competitor of the transcription factor c-Myb on tumor formation. We assume that fusion of the universal silencer KRAB to the DBD of any other oncogenic transcription factor, and thereby targeting to specific DNA sequences, may lead to a potent cancer therapy.
